Developing a Process to Assist Ukraine with Infusion Therapy During the Russian Invasion: PROJECT UKRAINE

INTRODUCTION

Since the February 2022 conflict, massive destruction of buildings has left many homeless, without electricity, or access to healthcare. The Insignis[™] Syringe Infusion System delivers the critical infusion of medications without the use of electricity and is portable, rugged, and reliant. This novel syringe-based mechanical infusion system is intended for the intravenous and subuctaneous infusion of medications. Innovative Health Sciences is patient-centric and wholly commited to improving the lives of patients worldwide.

METHOD

First, deciding the value of the product for Ukrainian patients was imperative. Knowing that patients who most required treatment may not have electricity, even if they have medical supplies, was a clear indication that the Insignis™ system was desperately needed. Next, it was essential to find dedicated medical professionals willing to with careful consideration given to education and safety. The process included vetting medical professionals who demonstrated a thorough understanding of the system, as well as appointing a contact for receipt and disbursement of medical supplies, shipping, education, and follow-through.

RESULTS

A mutual contact recommended Ukrainian physicians to view and demo the infusion system at the International Primary Immunodeficiency Conference (IPIC). The physicians agreed that an infusion system that operates without electricity or costly ancillaries was indispensable in Ukraine at this time. Infusion supplies were delivered to the mutual contact in Poland and a virtual visit with eight Ukrainian physicians provided essential education as well as a live demonstration of a subcutaneous Immunoglobulin infusion. © 2022 Innovative Health Sciences LLC. All Rights Reserved.

M. Bullock, M. Baker, A. Sealfon, N. Manatos, T. Kilcoin, R. Gani, M. Habib











DISCUSSION

1,000 Insignis Syringe Drivers and 20,000 administration sets were allocated for Ukrainian patients - but providing medical supplies was not enough to ensure the success of the project. The goal of Project Ukraine is to provide infusion systems that will help patients receive their medications, which are otherwise inaccessible. Our contact physician in Poland informed us that numerous Primary Immunodeficiency patients had not been able to receive their Intravenous Immunoglobulin for months and were fearful of contracting life-threatening infections in a war-ravaged country. Our initial interactions unearthed various challenges, but we were able to overcome these using a collaborative approach. Upon receipt of the supplies, a virtual visit with eight physicians and healthcare professionals provided the necessary education optimization. safety, f∩r

CONCLUSION

The first patient to use the Insignis system was a pediatric Primary Immunodeficiency patient. The caregiver (patient's mother) was trained in a clinic and then provided supplies and medication to perform the infusion with her son at home. In place of intravenous immunoglobulin, the child was introduced to subcutaneous Ig. As more patients use the Insignis system, it is crucial to provide continual training to ascertain sustainability, safety, and quality care for patients. Ongoing communication is vital to ensuring the mission's success and its impact on Primary Immunodeficiency patients in a war-ravaged country.

References:

Green R. Guidance on Switching from Intravenous Immunoglobulin (IVIg) to Subcutaneous Immunoglobulin (SCIg) Therapy. National Plasma Product Expert Advisory Group. Version 3. June 2018.



"Thank you also for your live presentation. I believe that seeing it like this is much better than even the best instruction or video. ()"

- The training as described by an attendee.



1108 Kings Highway, Suite #4 Chester, NY 10918 USA +1-855-680-0630 | www.innohealthsci.com